Ma XX, Wang XH. Rabeprazole sodium combined with mosapride and ursodeoxycholic acid for treatment of reflux esophagitis in Han, Hui and Tibetan patients.
Shijie Huaren Xiaohua Zazhi 2014;
22:4807-4809. [DOI:
10.11569/wcjd.v22.i31.4807]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To investigate the clinical efficacy of rabeprazole sodium combined with mosapride and ursodeoxycholic acid in the treatment of reflux esophagitis (RE) in patients of different ethnicity.
METHODS: From January 2013 to June 2014, Han, Hui and Tibetan patients (n = 60 for each ethnicity) with RE were treated with rabeprazole sodium, mosapride and ursodeoxycholic acid. After 8 wk of treatment, clinical symptoms were observed, and gastroscopy examination was performed.
RESULTS: After 8 wk of treatment, clinical symptoms were significantly reduced in all the three groups of patients; the total response rate had no statistical difference among the three group (95.00% vs 91.67% vs 93.33%, P > 0.05); and no serious adverse reactions were observed in any group.
CONCLUSION: Rabeprazole sodium combined with mosapride and ursodeoxycholic acid has good therapeutic effects on RE in Han, Hui and Tibetan patients.
Collapse